Scott Armstrong, MD, PhD
President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Chairman, Pediatric Oncology, Dana-Farber Cancer Institute; Associate Chief, Division of Hematology/Oncology, Boston Children’s Hospital
David G. Nathan Professor of Pediatrics, Harvard Medical School
Image
Scott Armstrong, MD, PhD
President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Chairman, Pediatric Oncology, Dana-Farber Cancer Institute; Associate Chief, Division of Hematology/Oncology, Boston Children’s Hospital
David G. Nathan Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Medical School
University of Texas Southwestern Medical School
1996
Dallas
TX
Internship
Boston Combined Residency Program (BCRP)
1998
Boston
MA
Residency
Boston Combined Residency Program (BCRP)
1998
Boston
MA
Fellowship
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
2001
Boston
MA
Professional History
Scott A. Armstrong, MD, PhD, became the President of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center in 2019 and has been Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute since 2016. He also serves as Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital. He was previously the Director of the Center for Epigenetics Research at Memorial Sloan Kettering Cancer Center and Professor of Pediatrics at the Weill Cornell Medical College. Dr. Armstrong earned his medical degree and his PhD from University of Texas Southwestern Medical School in 1996. After internship and residency training with the Boston Combined Residency Program (BCRP) at Boston Medical Center and Boston Children’s Hospital, he completed a hematology/oncology fellowship at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
The major focus of his career has been on delineating the biology of childhood cancers and the development of new therapeutic approaches for children with cancer. His research program has focused on the mechanisms of leukemia development and the relationship between leukemia and normal hematopoietic stem cells. He continues to direct a vigorous research program that focuses on development of new therapeutics that target chromatin based mechanisms, and he is actively involved in the development and translation of a number of new small molecule approaches that likely will be tested in clinical trials in the near future.
Publications
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wildtype p53 to Exert the Dominant-Negative Effect. View Abstract
Targeting the Menin-KMT2A interaction in leukemia: Lessons learned and future directions. View Abstract
Epigenetic Therapies. View Abstract
Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia. View Abstract
Revumenib Revises the Treatment Landscape for KMT2A-r Leukemia. View Abstract
NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML. View Abstract
CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant Cells. View Abstract
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. View Abstract
A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes. View Abstract
PI3K? maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. View Abstract
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML. View Abstract
Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery. View Abstract
Inherited blood cancer predisposition through altered transcription elongation. View Abstract
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. View Abstract
The future of HOXA- expressing leukemias: Menin inhibitor response and resistance. View Abstract
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. View Abstract
KDM6A epigenetically regulates subtype plasticity in small cell lung cancer. View Abstract
UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability. View Abstract
MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer. View Abstract
MEN1 mutations mediate clinical resistance to menin inhibition. View Abstract
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. View Abstract
Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia. View Abstract
A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition. View Abstract
SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. View Abstract
MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. View Abstract
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. View Abstract
Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. View Abstract
Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. View Abstract
MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape. View Abstract
The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. View Abstract
Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold? View Abstract
YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. View Abstract
Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever. View Abstract
Taspase1 orchestrates fetal liver hematopoietic stem cell and vertebrae fates by cleaving TFIIA. View Abstract
High-resolution characterization of gene function using single-cell CRISPR tiling screen. View Abstract
A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML. View Abstract
Histone PTM Crosstalk Stimulates Dot1 Methyltransferase Activity. View Abstract
Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition. View Abstract
HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. View Abstract
Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation. View Abstract
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. View Abstract
Author Correction: PGBD5 promotes site-specific oncogenic mutations in human tumors. View Abstract
Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. View Abstract
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. View Abstract
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition. View Abstract
It's Not What You Say But How You Say It: Targeting RNA Methylation in AML. View Abstract
Chromatin Complexes Maintain Self-Renewal of Myeloid Progenitors in AML: Opportunities for Therapeutic Intervention. View Abstract
Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. View Abstract
Higher-Order Linearization and Regularity in Nonlinear Homogenization. View Abstract
Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination during Lymphoid Development. View Abstract
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. View Abstract
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. View Abstract
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia. View Abstract
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. View Abstract
Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia. View Abstract
Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1. View Abstract
Targeting chromatin complexes in fusion protein-driven malignancies. View Abstract
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. View Abstract
IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. View Abstract
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. View Abstract
Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. View Abstract
Improved potency and reduced toxicity of the antifungal peptoid AEC5 through submonomer modification. View Abstract
HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. View Abstract
Location, Location, Location: Mutant NPM1c Cytoplasmic Localization Is Required to Maintain Stem Cell Genes in AML. View Abstract
Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. View Abstract
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. View Abstract
A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. View Abstract
LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPa-dependent enhancers in AML. View Abstract
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. View Abstract
Peptidomimetic blockade of MYB in acute myeloid leukemia. View Abstract
Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia. View Abstract
SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. View Abstract
Erratum: PGBD5 promotes site-specific oncogenic mutations in human tumors. View Abstract
miR-99 regulates normal and malignant hematopoietic stem cell self-renewal. View Abstract
A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. View Abstract
PGBD5 promotes site-specific oncogenic mutations in human tumors. View Abstract
Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. View Abstract
Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. View Abstract
Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations. View Abstract
Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. View Abstract
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. View Abstract
ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. View Abstract
Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. View Abstract
NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. View Abstract
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. View Abstract
Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus. View Abstract
Histone acetyltransferase activity of MOF is required for adult but not early fetal hematopoiesis in mice. View Abstract
Discovery and Characterization of a Peptoid with Antifungal Activity against Cryptococcus neoformans. View Abstract
AACR Cancer Progress Report 2016. View Abstract
Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML. View Abstract
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. View Abstract
Forward genetic screen of human transposase genomic rearrangements. View Abstract
The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. View Abstract
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. View Abstract
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". View Abstract
Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. View Abstract
The role of DOT1L in the maintenance of leukemia gene expression. View Abstract
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. View Abstract
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. View Abstract
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. View Abstract
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. View Abstract
Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia. View Abstract
MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. View Abstract
Editorial overview: Differentiation and disease. View Abstract
Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. View Abstract
A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence. View Abstract
Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. View Abstract
JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. View Abstract
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. View Abstract
Loss of BAP1 function leads to EZH2-dependent transformation. View Abstract
The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79. View Abstract
Mediator kinase inhibition further activates super-enhancer-associated genes in AML. View Abstract
Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. View Abstract
Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model. View Abstract
Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. View Abstract
Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia. View Abstract
DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. View Abstract
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. View Abstract
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. View Abstract
Structure-guided DOT1L probe optimization by label-free ligand displacement. View Abstract
Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia's genetic diversity. View Abstract
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. View Abstract
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. View Abstract
AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. View Abstract
Erratum: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. View Abstract
Far infrared laser polarimetry and far forward scattering diagnostics for the C-2 field reversed configuration plasmas. View Abstract
Langmuir probe diagnostic suite in the C-2 field-reversed configuration. View Abstract
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. View Abstract
Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. View Abstract
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. View Abstract
DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. View Abstract
Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. View Abstract
Sleep disruption in tetraplegia: a randomised, double-blind, placebo-controlled crossover trial of 3?mg melatonin. View Abstract
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. View Abstract
Genomic dark matter sheds light on EVI1-driven leukemia. View Abstract
Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. View Abstract
Evidence of the biochemical basis of host virulence in the greenbug aphid, Schizaphis graminum (Homoptera: Aphididae). View Abstract
Targeting epigenetic regulators for cancer therapy. View Abstract
Stem cells: Dual response to Ras mutation. View Abstract
KRas(G12D)-evoked leukemogenesis does not require ß-catenin. View Abstract
Pathprinting: An integrative approach to understand the functional basis of disease. View Abstract
In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. View Abstract
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. View Abstract
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-a in a murine model of polycythemia vera. View Abstract
DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. View Abstract
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. View Abstract
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. View Abstract
The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. View Abstract
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. View Abstract
Cancer. Can one cell influence cancer heterogeneity? View Abstract
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. View Abstract
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. View Abstract
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. View Abstract
A systemic approach to containing health care spending. View Abstract
EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. View Abstract
Genetic and pharmacologic inhibition of ß-catenin targets imatinib-resistant leukemia stem cells in CML. View Abstract
Polycomb repressive complex 2 is required for MLL-AF9 leukemia. View Abstract
Chromatin-modifying enzymes as modulators of reprogramming. View Abstract
Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. View Abstract
iCanPlot: visual exploration of high-throughput omics data using interactive Canvas plotting. View Abstract
Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. View Abstract
A role for DOT1L in MLL-rearranged leukemias. View Abstract
The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. View Abstract
eXframe: reusable framework for storage, analysis and visualization of genomics experiments. View Abstract
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. View Abstract
Self-renewal related signaling in myeloid leukemia stem cells. View Abstract
Differential niche and Wnt requirements during acute myeloid leukemia progression. View Abstract
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. View Abstract
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. View Abstract
The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. View Abstract
Cancer: The flipside of Notch. View Abstract
Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. View Abstract
Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. View Abstract
Targeting epigenetic programs in MLL-rearranged leukemias. View Abstract
Genetics, epigenetics, and leukemia. View Abstract
DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. View Abstract
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. View Abstract
MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. View Abstract
A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. View Abstract
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. View Abstract
Teladorsagia circumcincta: activation-associated secreted proteins in excretory/secretory products of fourth stage larvae are targets of early IgA responses in infected sheep. View Abstract
HELP for AML: methylation profiling opens new avenues. View Abstract
Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. View Abstract
miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. View Abstract
Transformation from committed progenitor to leukemia stem cells. View Abstract
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. View Abstract
Chromatin maps, histone modifications and leukemia. View Abstract
Screening and characterization of monoclonal antibodies to the surface antigens of Listeria monocytogenes serotype 4b. View Abstract
Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis. View Abstract
Gene expression profiling of leukemia stem cells. View Abstract
Leukemia stem cells and human acute lymphoblastic leukemia. View Abstract
HOXA9 is required for survival in human MLL-rearranged acute leukemias. View Abstract
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. View Abstract
Linking miRNA regulation to BCR-ABL expression: the next dimension. View Abstract
Cancer: inappropriate expression of stem cell programs? View Abstract
Cancer stem cells in hematopoietic malignancies. View Abstract
Cancer Stem Cells in Hematopoietic Malignancies. View Abstract
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. View Abstract
MLL translocations, histone modifications and leukaemia stem-cell development. View Abstract
Defining leukemia stem cells in MLL-translocated leukemias: implications for novel therapeutic strategies. View Abstract
Mixed lineage leukemia translocations and a leukemia stem cell program. View Abstract
MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. View Abstract
Therapeutic implications of leukemia stem cell development. View Abstract
FLT3 as a therapeutic target in childhood acute leukemia. View Abstract
Genome-wide SNP analysis in cancer: leukemia shows the way. View Abstract
High-throughput oncogene mutation profiling in human cancer. View Abstract
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. View Abstract
Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. View Abstract
Microarrays to identify new therapeutic strategies for cancer. View Abstract
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. View Abstract
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. View Abstract
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. View Abstract
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. View Abstract
Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. View Abstract
Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. View Abstract
Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. View Abstract
Molecular genetics of acute lymphoblastic leukemia. View Abstract
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. View Abstract
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. View Abstract
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. View Abstract
FLT3 mutations in childhood acute lymphoblastic leukemia. View Abstract
MLL-rearranged leukemias: insights from gene expression profiling. View Abstract
Comparison of human genomics and genetic models of cancer to identify novel therapeutic targets. View Abstract
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. View Abstract
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. View Abstract
Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. View Abstract
Genomic approaches to the pathogenesis and treatment of acute lymphoblastic leukemias. View Abstract
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. View Abstract
Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. View Abstract
Amplification of AML1 in childhood acute lymphoblastic leukemias. View Abstract
Cytogenetics for the model system Arabidopsis thaliana. View Abstract
Role and regulation of phospholipase D signalling. View Abstract
Casein kinase II-mediated phosphorylation of the C terminus of Sp1 decreases its DNA binding activity. View Abstract
Drosophila CBP is a co-activator of cubitus interruptus in hedgehog signalling. View Abstract
Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. View Abstract
cDNA cloning of component A of Rab geranylgeranyl transferase and demonstration of its role as a Rab escort protein. View Abstract
cDNA cloning and expression of the alpha and beta subunits of rat Rab geranylgeranyl transferase. View Abstract
The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. I. Gait analysis and radiological and morphological studies. View Abstract
The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. II. Cartilage composition and proteoglycan metabolism. View Abstract
Animal models of early osteoarthritis: their use for the evaluation of potential chondroprotective agents. View Abstract
The metabolic response of articular cartilage to abnormal mechanical loading induced by medial or lateral meniscectomy. View Abstract
Breath-actuated inhalers in chronic asthma: comparison of Diskhaler and Turbohaler for delivery of beta-agonists. View Abstract
Chondroprotection and NSAIDs. View Abstract
In vitro splenic IgG synthesis in Hodgkin's disease. View Abstract